Prostate Cell News Volume 6.03 | Jan 30 2015

OTUB1 De-Ubiquitinating Enzyme Promotes Prostate Cancer Cell Invasion In Vitro and Tumorigenesis In Vivo
RNAi screening was used to investigate the role of the ovarian tumor proteases family of deubiquitinating enzymes on the proliferation and invasion capacity of prostate cancer cells. [Mol Cancer] Abstract | Full Article

Targeting TR4 Nuclear Receptor Suppresses Prostate Cancer Invasion via Reduction of Infiltrating Macrophages with Alteration of the TIMP-1/MMP2/MMP9 Signals
Knocking-down TR4 nuclear receptor 4 (TR4) in human prostate cancer (PCa) cells, but not in human macrophages cells, led to suppress the macrophages infiltration to PCa cells. [Mol Cancer]
Abstract | Full Article

Inhibition of Prostate Smooth Muscle Contraction and Prostate Stromal Cell Growth by the Inhibitors of Rac, NSC23766 and EHT1864
Researchers investigated the role of Rac for the control of smooth muscle tone in the human prostate and growth of prostate stromal cells. Experiments were performed using human prostate tissues from radical prostatectomy and cultured stromal cells. [Br J Pharmacol] Abstract

miR-204 Is Dysregulated in Metastatic Prostate Cancer In Vitro
Scientists investigated miR-204 in the context of prostate cancer progression using a cell line model of different levels of genome instability, as demonstrated by the availability of ERG fusion. They studied the effect of miR-204 modulation on master transcription factors important for lineage development, cell differentiation and prostate cancer bone marrow metastasis. [Mol Carcinog] Abstract

γ-Oryzanol Reduces Caveolin-1 and PCGEM1 Expression, Markers of Aggressiveness in Prostate Cancer Cell Lines
Researchers found that γ-oryzanol decreases cell viability and culture biomass by apoptosis and/or necrosis death in androgen unresponsive and responsive cell lines, and signals through pERK1/2 in LNCaP and DU145 cells. [Prostate] Abstract

The Role of NFATc1 in Prostate Cancer Progression: Cyclosporine A and Tacrolimus Inhibit Cell Proliferation, Migration, and Invasion
Scientists determined the expression levels of nuclear factor of activated T-cells (NFAT) in prostate cell lines and tissue specimens. They then assessed the effects of NFAT inhibition via NFATc1-small interfering RNA as well as immunosuppressants including cyclosporine A and tacrolimus on prostate cancer cell proliferation, apoptosis, migration, and invasion in vitro and in vivo. [Prostate] Abstract

TGF-β and EGF Induced HLA-I Downregulation Is Associated with Epithelial-Mesenchymal Transition (EMT) through Upregulation of Snail in Prostate Cancer Cells
Scientists demonstrate that TGF-β and EGF both downregulated the expression of human leukocyte antigen class I antigens (HLA-I), thereby attenuated the cytotoxic T cell mediated lysis of prostate cancer cells. [Mol Immunol] Abstract

Effects of Zoledronic Acid and Docetaxel on Small GTP-Binding Proteins in Prostate Cancer
PC-3 cells were treated with clinically relevant concentrations of docetaxel and zoledronic acid either as single agents or in sequence and combination. Zoledronic acid followed by docetaxel was the best regimen producing the greatest reduction in cell viability and increase in apoptosis. [Tumor Biol] Abstract

Long-Term Exposure to Leptin Enhances the Growth of Prostate Cancer Cells
Researchers investigated the effect of leptin on prostate cancer (PCa) cell aggressiveness. Long-term exposure of PCa cells to leptin enhanced their proliferation, migration and invasion. [Int J Oncol] Abstract

CLINICAL RESEARCH

Phase III, Randomized, Double-Blind, Multicenter Trial Comparing Orteronel (TAK-700) plus Prednisone with Placebo lus Prednisone in Patients with Metastatic Castration-Resistant Prostate Cancer That Has Progressed during or after Docetaxel-Based Therapy: ELM-PC 5
Orteronel is an investigational, nonsteroidal, reversible, selective 17,20-lyase inhibitor. Researchers examined orteronel in patients with metastatic castration-resistant prostate cancer that progressed after docetaxel therapy. [J Clin Oncol] Abstract

Lenalidomide and Cyclophosphamide Immunoregulation in Patients with Metastatic, Castration-Resistant Prostate Cancer
Lenalidomide (LEN) and metronomic cyclophosphamide (CTX) regulate angiogenesis and immunosuppressive cells linked to the progression of metastatic castration-resistant prostate cancer (mCRPC). A Phase-I/II, dose-escalation trial of LEN plus oral CTX was conducted in patients with previously treated mCRPC. [Clin Exp Metastasis] Abstract

Visit our reviews page to see a complete list of reviews in the prostate cell research field.

UC San Francisco, UC San Diego Institutes Launch Major New Cancer Cell Mapping Initiative
Researchers from the University of California, San Diego School of Medicine and University of California, San Francisco, with support from a diverse team of collaborators, have launched an ambitious new project – dubbed the Cancer Cell Map Initiative or CCMI – to determine how all of the components of a cancer cell interact. [QB3 (PR Newswire Association LLC.)] Press Release

From our sponsor: Learn about assays for cord blood. Download the free technical bulletin.

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)

Visit our events page to see a complete list of events in the prostate cell community.

Postdoctoral Researcher – Prostate Cancer (Spanish National Cancer Research Centre [CNIO])

Postdoctoral Researcher – Prostate Cancer (University of Pennsylvania)

Director (California Institute for Regenerative Medicine)

Postdoctoral Research Fellow – Post-Transcriptional Gene Regulation Governing Cancer Cell Behavior (Fred Hutchinson Cancer Research Center)

Postdoctoral Fellow – Wnt Signaling in Development and Disease (Van Andel Research Institute)

Postdoctoral Fellow – Prostate Cancer Epigenetics and Genomics (UT Southwestern)

PhD Studentship – Chemokine Receptor in Prostate Cancer Metastasis (University of East Anglia)

Postdoctoral Research Associate Positions – Cancer Biology (Hollings Cancer Center)

Scientist – Prostate Cell Research (STEMCELL Technologies Inc.)

Scientist – Cell Culture Support Products (STEMCELL Technologies Inc.)

Recruit Top Talent: Reach more than 50,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.